ALMR

Alamar Biosciences Inc

28.94

Nov 02 • 3:59 PM ET -1.66 (-5.42%)

29.50

Aftermarket • 5:04 PM ET +0.56 (1.94%)

Healthcare Medical Devices USA Mid NASD

Nov 02, 8:05 AMAlamar Biosciences launches 80,000-sample UK Biobank neurodegenerative disease study with Nightingale Health using its NULISA proteomics platform

Peers: QTRX ILMN TXG QSI TECH SEER BRKR TMO LAB NAUT

| Held by: ARKG VTI IWM VXF VTWO IWO SCHA LFSC IWN ONEQ

Scroll to Statements

Index	RUT
Market Cap	2.01B
Enterprise Value	1.81B
Income	-
Sales	-
Book/sh	4.51
Cash/sh	3.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	222
IPO	Apr 17, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.42
P/C	8.03
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.23
Current Ratio	11.85
Debt/Eq	0.16
LT Debt/Eq	0.16
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-0.59
EPS next Q	-0.20
EPS this Y	-455.49%
EPS next Y	49.13%
EPS next 5Y	-10.86%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Nov 03 AMC
EPS/Sales Surpr.	28.55% 13.69%

Insider Own	48.36%
Insider Trans	-3.45%
Inst Own	24.86%
Inst Trans	43.39%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.91%
SMA50	-5.24%
SMA200	7.42%
Trades

Shs Outstand	69.39M
Shs Float	35.83M
Short Float	7.47%
Short Ratio	4.95
Short Interest	2.68M
52W High	39.61 -26.94%
52W Low	18.84 53.57%
Volatility	8.96% 10.86%
ATR (14)	2.70
RSI (14)	47.25
Beta	-
Rel Volume	1.62
Avg Volume	540.50K
Volume	875,856

Perf Week	-4.77%
Perf Month	-15.77%
Perf Quarter	6.75%
Perf Half Y	21.80%
Perf YTD	28.05%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.40
Target Price	35.40
Prev Close	30.60
Price	28.94
Change %	-5.42%

Consensus

Strong Buy

Avg. Price Target

$35.40

Implied Upside

+22.3%

Analysts5incl. previous ratings

Rating Distribution4 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 12, 2026	Initiated	TTD Cowen	Buy	$30	+3.7%
May 12, 2026	Initiated	SStifel	Buy	$28	-3.2%
May 12, 2026	Initiated	LLeerink Partners	Outperform	$35	+20.9%
May 12, 2026	Initiated	JJP Morgan	Overweight	$30	+3.7%
May 12, 2026	Initiated	BBofA Securities	Neutral	$27	-6.7%

Nov-02-26 07:05PM	UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study (GlobeNewswire) -5.42%
08:00AM	Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study (GlobeNewswire)
Oct-28-26 04:05PM	Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology (GlobeNewswire) +7.42%
Oct-26-26 06:44PM	Alamar Biosciences Faces A Higher Bar On Growth As Bearish Sentiment Builds (Earnings Whispers) +5.07%
Oct-08-26 04:05PM	Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026 (GlobeNewswire) -6.70%
04:05PM	Loading…
Oct-05-26 04:05PM	Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team (GlobeNewswire) +10.97% -15.39%
Sep-24-26 06:51PM	Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment (GlobeNewswire)
Sep-01-26 04:05PM	Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-26 01:02AM	Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ... (GuruFocus.com) +30.65%
Aug-10-26 04:38PM	Alamar: Q2 Earnings Snapshot (Associated Press)
04:05PM	Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance (GlobeNewswire)
04:03PM	Alamar Biosciences Expands Global Partnership with Alzheimer's Disease Data Initiative and Gates Ventures (GlobeNewswire)
Aug-05-26 08:05AM	Attovia adds to biotech IPO momentum with $289M offering (BioPharma Dive)
Jul-28-26 04:12PM	Alamar Biosciences Launches NULISAseq Immune 340 Panel for Comprehensive Profiling of the Immune Proteome (GlobeNewswire)
Jul-15-26 07:34AM	Braveheart, Attovia join next wave of biotech IPOs (BioPharma Dive)
04:05PM	Loading…
Jul-14-26 04:05PM	Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 (GlobeNewswire)
Jul-13-26 04:50PM	Alamar Hits A High Note On Alzheimer's Buzz (Trefis)
02:30AM	Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases (GlobeNewswire)
Jul-10-26 06:11AM	Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling (GlobeNewswire) +7.33%
Jul-07-26 09:12AM	Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research (GlobeNewswire)
Jul-01-26 09:04AM	Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX (GuruFocus.com)
May-12-26 09:56AM	Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls (The Fly)
May-08-26 08:00AM	Alamar Biosciences Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:05PM	Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference (GlobeNewswire)
Apr-19-26 10:41PM	Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 28 '26	Sale	32.77	100,837	3,303,983	164,191	Oct 29 04:09 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 27 '26	Sale	31.39	84,894	2,664,905	165,953	Oct 29 04:09 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 23 '26	Sale	30.59	147,934	4,525,068	169,753	Oct 27 04:10 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 26 '26	Sale	30.52	132,524	4,044,691	167,438	Oct 27 04:10 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 21 '26	Sale	30.31	208,815	6,328,758	174,677	Oct 23 07:35 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 22 '26	Sale	29.33	133,811	3,924,337	172,338	Oct 23 07:35 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 20 '26	Sale	27.89	142,004	3,961,103	178,326	Oct 21 07:15 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 19 '26	Sale	26.34	75,508	1,988,881	180,808	Oct 21 07:15 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 15 '26	Sale	27.73	173,537	4,812,446	182,130	Oct 19 04:30 PM
Qiming Corporate GP VI, Ltd.	10% Owner	Oct 16 '26	Sale	27.02	136	3,675	182,128	Oct 19 04:30 PM
Qiming Venture Partners VIII-H	Affiliate	Oct 14 '26	Proposed Sale	23.52	435,468	10,242,000		Oct 14 08:33 PM
Qiming Venture Partners VIII I	Affiliate	Oct 14 '26	Proposed Sale	23.52	363,729	8,555,000		Oct 14 08:23 PM
Qiming Venture Partners VI, L.	Affiliate	Oct 14 '26	Proposed Sale	23.52	1,558,858	36,664,000		Oct 14 08:20 PM
Qiming Managing Directors Fund	Affiliate	Oct 14 '26	Proposed Sale	23.53	41,945	987,000		Oct 14 08:15 PM
Illumina Innovation Fund II GP	10% Owner	Apr 20 '26	Buy	17.00	235,294	3,999,998	507,076	Apr 20 08:45 PM
Naclerio Nicholas	Director	Apr 20 '26	Buy	17.00	235,294	3,999,998	507,076	Apr 20 08:31 PM

Alamar Biosciences, Inc. engages in developing a proteomic liquid biopsy platform and sells instruments, consumables & services for the early detection of diseases. Its products include ARGO HT system, NULISA assays for Immunology, neurology & oncology, NULISAqpcr custom assay development, technology access program and Alamar analysis solutions. The company was founded by Yuling Luo, Yiyuan Yin and Steve Chen in May 2018 and is headquartered in Fremont, CA.

Co-FounderDr. Yuling Luo Ph.D.

Co-FounderDr. Shiping Chen Ph.D.

Chief Financial OfficerMr. Justin J. McAnear

PresidentMr. Timothy Ogden White J.D.

Co-FounderMs. Yiyuan Yin Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMR

Alamar Biosciences Inc

Upgrade your Finviz experience